뉴스벤징가
Compass Pathways’ Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression
· 발표
기사 요약
Compass Pathways surges 11% after COMP360 Phase 3 trial shows durable 52-week relief for treatment-resistant depression.
기사 원문에서 발췌했어요.Compass Pathways surges 11% after COMP360 Phase 3 trial shows durable 52-week relief for treatment-resistant depression.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…